A newly published correction in Cancer Immunology, Immunotherapy has repaired two tables in a study examining haemostatic changes during chimeric antigen receptor T-cell therapy, commonly known as CAR T-cell therapy, and the risk of treatment-related complications. The correction, published by Springer Nature on 25 August 2026, addresses formatting failures that altered the visual alignment of patient characteristics and laboratory measurements in the original article. The authors emphasize that the problem arose during formatting and typesetting, not from a change in the underlying research data or conclusions.
The original study, published on 31 March 2026, investigated how CAR T-cell treatment affects the blood-clotting system. CAR T-cell therapy is an advanced form of immunotherapy in which a patient’s T lymphocytes are genetically modified to recognize and attack malignant cells. It has transformed treatment for several blood cancers, but the therapy can trigger powerful immune reactions and complex changes in the circulation. Among the complications clinicians monitor are bleeding, thrombosis, inflammation-associated coagulation abnormalities and changes in platelet or clotting-factor activity.
Haemostasis is the tightly regulated biological process that keeps blood fluid inside healthy vessels while allowing clots to form rapidly after injury. It depends on an interaction between platelets, coagulation proteins, blood vessels and inflammatory signals. In patients receiving CAR T-cell therapy, this balance can be disturbed by the conditioning chemotherapy given before the modified cells are infused, by the patient’s underlying cancer, by infection, by organ dysfunction and by immune toxicities associated with treatment. Severe inflammatory reactions may activate the endothelium, the cell layer lining blood vessels, and alter the behaviour of both platelets and coagulation factors.
The corrected version of Table 1 presents the baseline characteristics of the patients recruited for the study. According to the correction notice, a systematic formatting error affected several categorical variables, including sex, diagnosis, disease status before lymphodepletion and cardiovascular risk factors. In the original presentation, the value belonging to the first subcategory had been placed in the header row rather than beside its corresponding category. For example, the value for “Male” was not aligned correctly beneath the broader label “Sex, n (%)”. This shifted information across the first three columns and could make the patient population appear different from what the investigators had actually reported.
The final column of Table 1, which contained p-values, remained correctly positioned, according to the publisher’s notice. A p-value is used in statistical testing to estimate how compatible an observed difference is with a specified null hypothesis. Although such values can help readers assess whether groups differ statistically, they are meaningful only when the variables being compared are correctly identified and aligned. A displaced category can therefore create confusion even when the numerical data themselves have not changed. In a clinical study, that confusion may affect how readers interpret the balance of risk factors between groups or understand which patient subgroup a percentage describes.
Table 2 required a separate correction because a column shift occurred during typesetting. This table reports the dynamics of thrombin-generation variables and other haemostatic tests. Thrombin is a central enzyme in coagulation: it converts fibrinogen into fibrin, amplifies platelet activation and helps build the meshwork that stabilizes a blood clot. Tests of thrombin generation do not simply ask whether clotting occurs; they measure how rapidly thrombin appears, how high its production rises and how long the response persists. These measurements can provide a broader picture of a patient’s coagulation potential than conventional tests that focus on isolated clotting times.
The formatting error in Table 2 displaced the column containing parameter names, including measurements such as “Lag time (ratio)” and “Peak Height (%)”, into the column intended for baseline values. As a result, subsequent cells were misaligned. In thrombin-generation analysis, lag time generally refers to the delay before measurable thrombin production begins, while peak height describes the maximum thrombin concentration or activity reached during the assay. A ratio may express a value relative to a reference or baseline measurement. If these labels are separated from their numerical results, readers can no longer reliably determine which number corresponds to which biological variable.
The correction is particularly important because the study concerns haemostatic changes over the course of CAR T-cell treatment, a period in which laboratory values may change quickly. Patients may undergo lymphodepleting chemotherapy before infusion, experience early inflammatory responses and receive supportive treatments that affect blood counts or coagulation. Researchers comparing measurements at different time points must be able to distinguish baseline values from post-treatment results and identify the precise assay parameter being analyzed. Correctly formatted tables are therefore not a cosmetic detail; they are essential for reproducing analyses, comparing results across studies and translating findings into clinical questions.
The authors listed on the correction are María Panizo-Inogés, María Marcos-Jubilar, Jose Ramón González-Porras, Carlos Puerta-Vazquez, Clara Fernández-Arias, Paula Rodríguez-Otero, Ana Alfonso-Pierola, Sara Villar, Miguel Ángel Canales, Josune Orbe, Jose Antonio Páramo, Felipe Prósper and Ramón Lecumberri. Most are affiliated with the Hematology Department at Clínica Universidad de Navarra in Pamplona, Spain, while González-Porras and Puerta-Vazquez are affiliated with the Hematology Department at Hospital Universitario de Salamanca. The correction links directly to the original article and supplies corrected versions of both tables. Springer Nature states that the original article has now been amended.
For readers following the rapidly expanding field of CAR T-cell medicine, the notice offers a reminder of how vulnerable scientific communication can be to errors introduced after research has been completed. A typesetting mistake can alter the apparent meaning of a table without changing a single measurement in the investigators’ dataset. Corrections allow the scientific record to remain transparent while preserving the original work when the problem is limited to presentation. In this case, the published correction does not announce new patients, revised statistical analyses or different clinical conclusions. Instead, it restores the correct relationship between labels and values in a study focused on how cellular immunotherapy may reshape the machinery of blood coagulation.
Subject of Research: Haemostatic changes and risk of complications during CAR T-cell therapy
Article Title: Correction: Haemostatic changes during CART cell therapy and risk of complications
Article References: Original Article: “Haemostatic changes during CART cell therapy and risk of complications,” Cancer Immunology, Immunotherapy (2026) 75:130
Image Credits: AI Generated
DOI: 10.1007/s00262-026-04425-9
Keywords: CAR T-cell therapy, haemostasis, coagulation, thrombin generation, thrombosis, bleeding, immunotherapy, cancer, typesetting correction, clinical hematology
Tags: blood clotting complications in cancer treatmentblood vessel regulation during immunotherapyCAR-T Cell Therapycorrection and formatting errors in medical researchhaemostatic changes in immunotherapyimmune response and coagulation in blood cancersimmune-related coagulation abnormalitiesimpact of immunotherapy on platelet functionlaboratory measurement accuracy in clinical studiessafety monitoring of CAR T-cell treatmentsthrombosis in CAR T-cell therapytreatment-related bleeding risks
